PRINCETON, N.J. , Aug. 27, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that management will present at the following...
PRINCETON, N.J. , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari , President and Chief...
Completion of the SECURE Clinical Trial for Twirla® Planned for Second Half of 2016; Resubmission to the FDA Planned for the First Half of 2017...
PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...
PRINCETON, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that it has received net proceeds of approximately $6 million in...